To investigate the therapeutic potential of oncolytic adenoviruses against human CRC cells, we used three KRAS/BRAS wild-type human CRC cell lines, Colo320DM (MSS type), SW48 (MSI type), and CACO-2 (MSS type); three KRAS-mutant human CRC cell lines, SW620 (MSS type), DLD-1 (MSI type), and HCT116 (MSI type); and three BRAF-mutant human CRC cell lines, HT29 (MSS type), RKO (MSI type), and COLO205 (MSS type). This evidence concerns the gene BRAF and colorectal carcinoma.